17 February 2023 - Eisai anticipates about 100,000 patients diagnosed will be eligible for the drug by year three of its rollout.
US CEO Ivan Cheung said the FDA, which granted accelerated clearance in January, could give full approval as soon as July if the company gets an expedited “priority review” for demonstrating a significant improvement in how early Alzheimer’s is treated.